| Literature DB >> 29901726 |
Sei Hwan You1,2, Mee Yon Cho3, Joon Hyung Sohn4, Chang Geol Lee1.
Abstract
Pancreatic radiation effect (PRE) can be aEntities:
Mesh:
Substances:
Year: 2018 PMID: 29901726 PMCID: PMC6151648 DOI: 10.1093/jrr/rry043
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Fig. 1.Schematic diagrams of rat irradiation method. (A) Irradiation in concurrence to pancreas and rectum (iCPR) without shield. (B) iCPR with pancreatic shield. (C) iCPR with non-pancreatic shield.
Fig. 2.An example of a pancreatic shield and radiation planning process using a technique of irradiation in concurrence to pancreas and rectum (iCPR). (A) Postero–anterior beam’s eye view with contoured organs. (B) Actual radiation exposure after shield system application; pancreatic shield (PS, left) and non-pancreatic shield (NPS, right). (C) Rendered images of radiation planning for PS irradiation (left) and NPS irradiation (right) for postero–anterior/antero–posterior portals. (D) Dose profiles of PS (left) and NPS (right) applied to solid water phantom.
Group classification for male Sprague Dawley rats and their number allocation according to radiation dose, pancreatic shielding, and time phase after irradiation
| Group category | Pancreatic shield | Non-pancreatic shield |
|---|---|---|
| Early phase (1 week after irradiation) | ||
| 5 Gy | 6 | 6 |
| 15 Gy | 6 | 6 |
| Late phase (14 weeks after irradiation) | ||
| 5 Gy | 6 | 6 |
| 15 Gy | 6 | 6 |
Dosimetric comparison of mean doses of each contour volume for pancreatic shield (PS) and non-pancreatic shield (NPS) groups in seven sample rats, with a 500-cGy prescription using postero–anterior/antero–posterior X-rays
| Volume (ml)a | Mean dose (cGy)a | |||
|---|---|---|---|---|
| Pancreatic shield group | Non-pancreatic shield group | |||
| Liver | 8.51 ± 0.62 | 163.94 ± 16.60 | 135.37 ± 21.89 | 0.018 |
| Stomach | 3.78 ± 0.55 | 146.03 ± 32.82 | 95.96 ± 19.11 | 0.004 |
| Right kidney | 1.32 ± 0.13 | 127.87 ± 38.07 | 96.17 ± 39.33 | 0.151 |
| Left kidney | 1.22 ± 0.13 | 93.16 ± 21.77 | 38.94 ± 15.51 | <0.001 |
| Pelvic contourc | 36.93 ± 3.74 | 265.33 ± 15.76 | 264.29 ± 16.11 | 0.905 |
| Abdomino–pelvic contourd | 171.43 ± 8.74 | 103.59 ± 4.20 | 106.23 ± 4.27 | 0.265 |
| Pancreas | 1.86 ± 0.23 | 53.33 ± 9.90 | 464.04 ± 8.37 | <0.001 |
aThe values are shown as the mean ± standard error.
bStudent t test for mean doses of each contour volume, between the pancreatic shield and the non-pancreatic shield groups.
cThe pelvic contour, including all pelvic organs and skin area, was delineated from the anal verge to the 18th slice location upward, with a 2-mm thickness.
dThe abdomino–pelvic contour was delineated from the diaphragm to the anal verge level for integral dose assessment, as a substitute for the whole body, reflecting the radiosensitive gastrointestinal area.
Fig. 3.Changes in body weight (A) and fasting blood glucose (B) after irradiation. Data represent the mean and 95% confidence interval with six samples. Pairs of filled stars, empty stars and filled circles: P < 0.05.
Fig. 4.Apoptosis in rectal mucosa by hematoxylin–eosin stain. (A) to (D) Representative images of axial rectum tissue at the first week (early phase, Ep) after irradiation are shown for pancreatic shield (PS)-5-Gy (A), non-pancreatic shield (NPS)-5-Gy (B), PS-15-Gy (C), and NPS-15-Gy (D) groups. Black arrows, apoptotic bodies in the mucosa. Magnification, ×400. Scale bar, 25 μm. (E) Apoptotic index calculated by the number of apoptotic bodies per 100 crypts on axial rectal mucosa. The images at the 14th week (late phase, Lp) were not displayed due to relatively rare apoptotic bodies with unclear differences for each group. Data represent the mean and 95% confidence interval with six samples.
Fig. 5.Fibrotic changes in rectal mucosa by Picrosirius red (PR) staining. Representative images of the axial rectum tissue stained by hematoxylin–eosin (1), Masson’s trichrome (2), PR (3), and PR-stained area in a defined range of the mucosal layer (4) are shown for each group at the first week (early phase, Ep) and the 14th week (late phase, Lp). (A) Pancreatic shield (PS)-5-Gy-Ep group. (B) Non-pancreatic shield (NPS)-5-Gy-Ep group. (C) PS-15-Gy-Ep group. (D) NPS-15-Gy-Ep group. (E) PS-5-Gy-Lp group. (F) NPS-5-Gy-Lp group. (G) PS-15-Gy-Lp group. (H) NPS-15-Gy-Lp group. Magnification, ×100. Scale bar, 100 μm. (I) PR positivity calculated quantitatively. Data represent the mean and 95% confidence interval with six samples. Pairs of filled stars, empty stars, filled circles and empty circles: P < 0.05.
Fig. 6.Cleaved caspase-3 (CCP3)–positive cells by immunohistochemical staining. Representative images of the axial rectum tissue are shown for each group at the first week (early phase, Ep) and the 14th week (late phase, Lp). (A) Pancreatic shield (PS)-5-Gy-Ep group. (B) Non-pancreatic shield (NPS)-5-Gy-Ep group. (C) PS-15-Gy-Ep group. (D) NPS-15-Gy-Ep group. (E) PS-5-Gy-Lp group. (F) NPS-5-Gy-Lp group. (G) PS-15-Gy-Lp group. (H) NPS-15-Gy-Lp group. Magnification, ×400. Scale bar, 25 μm. (I) CCP3 positivity defined as the number of CCP3-positive cells per 100 epithelial cells in the crypts. Data represent the mean and 95% confidence interval with six samples. Pairs of filled stars and empty stars: P < 0.05.
Fig. 7.Relative mRNA expression (real time PCR using rat-specific primers) compared with one control subject at the first week (early phase, Ep) and the 14th week (late phase, Lp) after irradiation for each group. (A) Interleukin-6 (IL-6). (B) Hypoxia-inducible factor (HIF)-1α. (C) Vascular endothelial growth factor (VEGF)-A. (D) Nuclear factor (NF)-κB. Data represent the mean and 95% confidence interval of the results of three independent experiments, each with six samples. A significant Ep–Lp decrease pairs (P < 0.05) for the same dose and pancreatic shield condition are denoted as filled stars, empty stars, and filled circles.